15.04.2014 • NewsDede WillamsGlaxoSmithKline (GSK)GSK

GSK Faces Criminal Bribery Investigation in Poland

GlaxoSmithKline (GSK) is facing fresh allegations of corruption, following reported incidents in China and Iraq. Polish authorities have launched a criminal investigation against the UK's biggest drugmaker for allegedly bribing doctors to promote its lung drug Seretide, also known as Advair, which has worldwide sales of around $8 billion a year.

The country's Central Anti-Corruption Bureau, or CBA, said 13 people had been charged in the case.

GSK said a single employee had been disciplined for "inappropriate communication" in contravention of company policy, following an internal probe, adding that it was co-operating with the Polish authorities. The company said the allegations related to the way a respiratory disease programme was conducted in the Lodz region.

The UK's national broadcasting company, BBC, reported that the Polish investigation included 11 doctors and a GSK regional manager, charged over alleged corruption between 2010 and 2012. It said one doctor who admitted guilt was fined and given a suspended sentence, after accepting £100 pounds for a lecture he never gave.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.